Isolated cardiac metastasis after comprehensive treatment with hepatocellular carcinoma: a case report and literature review.

Acta Chir BelgMay 20, 2026 (epub)

Yu Yao, Ying-Jie Tang, Xiang Nong et al.

✦ AI-curated · Sources linked

Case in brief

A 61-year-old male with BCLC-B stage hepatocellular carcinoma (HCC) underwent liver resection and subsequent treatments, including immunotherapy and radiofrequency ablation. Three years post-surgery, imaging revealed an isolated mass in the right ventricle, diagnosed as cardiac metastasis of HCC. Despite treatment with lenvatinib and sintilimab, the patient died two weeks later from suspected cardiac rupture.

What made this case unusual

This case highlights the rare occurrence of isolated cardiac metastasis of HCC in the right ventricle, without involvement of the right atrium or inferior vena cava.

Diagnostic / clinical pearl

Clinicians should maintain a high index of suspicion for cardiac metastasis in HCC patients with multiple recurrences and rising alpha-fetoprotein levels, even after ruling out intrahepatic recurrence.

Why it matters

This case underscores the need for vigilant follow-up in HCC patients, particularly those with extensive treatment histories, to detect potential extrahepatic metastases early.

Source

Published in Acta Chir Belg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.